Quality Metrics & Ratings

CMS’s voluntary recalculation of 2026/2027 Medicare Advantage Star Ratings—following litigation pressure including Clover’s lawsuit—has intensified volatility around MA quality bonuses, with upside for some plans such as Humana and Clover but limited average-rating movement overall; for VBC stakeholders, the episode underscores how methodology disputes can directly affect billions in bonus payments and payer-provider contract economics (STAT, Healthcare Dive). At the provider level, the week’s commentary pointed to a parallel operational theme: success in models like CJR-X and independent-practice VBC increasingly depends on granular data infrastructure, automated outreach, and reducing quality-reporting burden rather than simply accepting downside risk. Together, the developments show quality measurement becoming both a financial flashpoint for payers and an execution challenge for providers as CMS under the Trump administration continues to shape incentives through ratings, bonus formulas, and model design.